MOBILITY COLLAGEN NOW LIVE — SECURE EFT CHECKOUT · EXPERIMENTAL PEPTIDES — RESEARCH INFORMATION ONLY · MOBILITY COLLAGEN NOW LIVE — SECURE EFT CHECKOUT · EXPERIMENTAL PEPTIDES — RESEARCH INFORMATION ONLY · MOBILITY COLLAGEN NOW LIVE — SECURE EFT CHECKOUT · EXPERIMENTAL PEPTIDES — RESEARCH INFORMATION ONLY · MOBILITY COLLAGEN NOW LIVE — SECURE EFT CHECKOUT · EXPERIMENTAL PEPTIDES — RESEARCH INFORMATION ONLY · MOBILITY COLLAGEN NOW LIVE — SECURE EFT CHECKOUT · EXPERIMENTAL PEPTIDES — RESEARCH INFORMATION ONLY · MOBILITY COLLAGEN NOW LIVE — SECURE EFT CHECKOUT · EXPERIMENTAL PEPTIDES — RESEARCH INFORMATION ONLY · MOBILITY COLLAGEN NOW LIVE — SECURE EFT CHECKOUT · EXPERIMENTAL PEPTIDES — RESEARCH INFORMATION ONLY · MOBILITY COLLAGEN NOW LIVE — SECURE EFT CHECKOUT · EXPERIMENTAL PEPTIDES — RESEARCH INFORMATION ONLY ·
Diesel, a dignified nine-year-old Boerboel on a warm cream background

PEPTIDES4PETS · SOUTH AFRICA

Pet research, made clear.

All five published catalogue products are in stock. Mobility Collagen is a pet nutritional supplement; experimental peptides are sealed research vials with animal evidence and study limits shown clearly.

  • Evidence graded
  • Report scope shown
  • South African fulfilment

THE LAUNCH BATCH

Five products. All in stock.

Order any published catalogue product by secure EFT for delivery in South Africa. Experimental peptides are supplied as sealed research vials with evidence grades and study limits.

BPC-157 Research Vial
LIVE — SHIPS NOW≥99% HPLC

BPC-157 Research Vial

Synthetic peptide powder with canine pharmacokinetic data and preclinical repair signals explained in context.

R895/VIAL

DETAILS →
KEY EVIDENCE (2)
  • CANINE PK STUDYIn a 2022 pharmacokinetic study in six beagle dogs, BPC-157 demonstrated 45–51% intramuscular bioavailability and was well tolerated across doses.FRONT PHARMACOL 2022 · PMC9794587
  • MARKET SIGNALUS pet peptide brands (e.g. Integrative Peptides' PetTides BPC-157, $99–$149) and reporting in Men's Health (2026) reflect established consumer demand for BPC-157 in pets.MARKET & MEDIA RESEARCH 2025–26
KPV Gut & Skin Research Vial
LIVE — SHIPS NOW≥99% HPLC

KPV Gut & Skin Research Vial

Synthetic peptide powder studied in gut-lining and skin-barrier inflammation models, with canine evidence gaps stated clearly.

R795/VIAL

DETAILS →
KEY EVIDENCE (2)
  • PRECLINICALIn mouse colitis models, the tripeptide KPV reduced intestinal inflammation and supported mucosal healing — the basis for its gut-lining reputation.PRECLINICAL GI RESEARCH
  • MARKET SIGNALKPV appears across US pet peptide catalogs positioned for gut and skin support, reflecting established consumer demand ahead of formal trials.MARKET RESEARCH 2025
Recovery Blend
LIVE — SHIPS NOW≥99% HPLC

Recovery Blend

Synthetic peptide powder covering two complementary repair-signalling research questions and the limits of canine evidence.

R1 195/VIAL

DETAILS →
KEY EVIDENCE (2)
  • COMMUNITY PRACTICEUS liquid blends (e.g. Protex Pets: BPC-157 250mcg + TB-500 100mcg, $64.99 / 30 servings) popularized this pairing among performance and rehab communities.MARKET RESEARCH 2025
  • CANINE PK STUDYThe BPC-157 half of this blend carries 2022 beagle pharmacokinetic data: 45–51% intramuscular bioavailability, well tolerated across doses.FRONT PHARMACOL 2022 · PMC9794587
Immune (Thymogen)
LIVE — SHIPS NOW≥99% HPLC

Immune (Thymogen)

Synthetic thymic-peptide powder for early immune-signalling research, with animal-evidence limits stated clearly.

R845/VIAL

DETAILS →
KEY EVIDENCE (1)
  • MARKET SIGNALThymic peptides (e.g. PetTides Immune-Peptide-A2) are established in US pet peptide catalogs for immune resilience positioning.MARKET RESEARCH 2025
Mobility Collagen
LIVE — SHIPS NOW≥99% HPLC

Mobility Collagen

Pet nutritional support informed by published canine mobility research.

R395/TUB

DETAILS →
KEY EVIDENCE (2)
  • CANINE RCTIn a 2024 randomized controlled trial (31 dogs, 12 weeks), bioactive collagen peptides (PETAGILE®) improved objective force-plate gait measures vs control.PLOS ONE 2024
  • CANINE STUDYUndenatured type-II collagen (UC-II) matched robenacoxib — a registered NSAID — on force-plate outcomes in canine osteoarthritis studies.CANINE OA RESEARCH

ALL FIVE PRODUCTS IN STOCK · SECURE EFT CHECKOUT · SEALED PEPTIDE RESEARCH VIALS · EVIDENCE LIMITS SHOWN

60-SECOND QUIZ

A clearer research starting point.

Three quick steps — the navigator organises the evidence.

  1. 1

    Tell us about your pet

    Species, age, size and what matters most.

  2. 2

    Compare evidence profiles

    See study type, evidence gaps and document scope side by side.

  3. 3

    Save research interests

    Join research updates — no payment and no treatment recommendation.

STUDY TYPE SHOWN · REPORT SCOPE DISCLOSED · EVIDENCE GAPS PUBLISHED

READ THE SCIENCE

FROM OUR FOUNDER

One dog. Three clips. An honest account.

Meet our founder’s dog through three owner-submitted videos, with context on what personal observations can—and cannot—tell us.

Watch the three-clip diary →

The South African pet journal

Evidence and practical questions to discuss with your veterinarian.

Read all articles

RESEARCH PEPTIDES ARE SUPPLIED AS SEALED LYOPHILISED-POWDER VIALS · MOBILITY COLLAGEN IS A NUTRITIONAL SUPPLEMENT, NOT A VETERINARY MEDICINE · REGULATORY STATUS IS PRODUCT-SPECIFIC · ALWAYS CONSULT YOUR VETERINARIAN

Your basket

Your basket is empty.

Shop now